Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio.
Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.
Irland, UK, RussiaHeadquarters
17 Pembroke Upper Street, D02 AT22 Dublin 2 – Ireland
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.